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Introduction {#sec1}
============

The centrosome is the principal microtubule (MT) organizing center in animal cells and consists of a pair of centrioles surrounded by the pericentriolar material (PCM) ([@bib6]). The centrosome is duplicated once per cell cycle during S-phase to ensure that at the onset of mitosis, cells have two centrosomes. The importance of the centrosome cycle is emphasized by its tight regulation and conservation throughout evolution ([@bib54], [@bib78]). However, cancer cells often display centrosomal abnormalities; in particular, centrosome amplification has been extensively characterized in both solid and hematological malignancies ([@bib13], [@bib47], [@bib81]). Mounting evidence indicates that extra centrosomes are not bystanders of tumor progression and can directly impact tumorigenesis by generating aneuploidy and promoting the acquisition of invasive traits ([@bib28], [@bib31]). Furthermore, recently developed mouse models demonstrated that induction of centrosome amplification, via transient Polo-like kinase 4 (PLK4) overexpression, not only accelerates tumorigenesis in the absence of the tumor suppressor p53 ([@bib18], [@bib64]) but also promotes tumor formation in p53-proficient mice ([@bib42]). Therefore, centrosome amplification can play a role in the initiation and progression of tumors.

Intriguingly, the presence of supernumerary centrosomes comes with a cost ([@bib59]). Cells with extra centrosomes divide slower and require efficient mechanisms that enable the formation of a "pseudo-bipolar" spindle during mitosis (e.g., centrosome clustering) to prevent catastrophic multipolar division ([@bib4], [@bib28], [@bib41], [@bib60]). Furthermore, in cells with intact tumor suppressors, centrosome amplification induces p53-mediated cell-cycle arrest ([@bib26], [@bib37]). Thus, while it is predictable that cells with extra centrosomes undergo negative selection *in vitro* ([@bib40], [@bib51]), it is perhaps counterintuitive that *in vivo* tumors maintain "less-fit" cells carrying centrosomal abnormalities. This is particularly surprising given tumor heterogeneity, where most human tumors display high genetic and phenotypic diversity ([@bib49]), including heterogeneous centrosome numbers ([@bib13]). Thus, why are cells with extra centrosomes not outcompeted during tumor evolution? It is becoming clear that tumor evolution cannot be merely explained by positive selection of the fittest clones ([@bib49], [@bib71]). In fact, widespread intratumor heterogeneity (ITH) challenges the idea that the dominant subclone solely drives tumor phenotypes in a cell autonomous manner ([@bib49]). Using mouse xenograft models, Polyak and colleagues found that a subclone overexpressing interleukin (IL)-11 acted as a non-cell-autonomous driver of tumor growth and was essential to maintain ITH by promoting the growth of less-fit clones ([@bib48]). Here, we set out to investigate whether cells with extra centrosomes play non-cell-autonomous roles that could benefit the surrounding cells and explain their maintenance in tumors.

Results {#sec2}
=======

Centrosome Amplification Induces Paracrine Invasion {#sec2.1}
---------------------------------------------------

To investigate whether the presence of extra centrosomes promotes non-cell-autonomous functions, we took advantage of non-transformed cells to avoid additional effects caused by cancer mutations. To do so, conditioned media (CM) was collected from our previously established human mammary epithelial cell line MCF10A.PLK4 (donor \[D\] cells) where centrosome amplification is driven by transient induction of PLK4 upon doxycycline (DOX) treatment ([@bib31]) ([Figure S1](#mmc1){ref-type="supplementary-material"}A). CM collected at 16, 24, and 36 hr from donor cells was added on top of recipient (R) MCF10A cells grown in 3D cultures, which form acinar structures ([Figure 1](#fig1){ref-type="fig"}A). Strikingly, CM collected from cells with extra centrosomes (CM+DOX) was able to induce a robust invasive phenotype (∼20%), characterized by the formation of actin-rich invasive protrusions capable of degrading the basement membrane ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}B). We previously found that centrosome amplification was sufficient to drive invasion in a cell-autonomous manner ([@bib31]); however, paracrine invasion was not a consequence of increased centrosome numbers in the recipient cells ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Live cell imaging of 3D acini treated with CM shows how these invasive protrusions enable collective migration through the extracellular matrix (ECM) ([Videos S1](#mmc6){ref-type="supplementary-material"} and [S2](#mmc7){ref-type="supplementary-material"}) and allow cells to invade the surrounding environment ([Figure S1](#mmc1){ref-type="supplementary-material"}C; [Videos S3](#mmc8){ref-type="supplementary-material"} and [S4](#mmc9){ref-type="supplementary-material"}). When compared with invasive protrusions induced directly by extra centrosomes, protrusions induced by the CM+DOX appeared morphologically distinct, containing increased percentages of nuclei (∼23% as opposed to ∼5%) ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Moreover, when added on top of cells with extra centrosomes (+DOX), CM+DOX further increased invasion, with many of the structures displaying a more severe and abnormal invasive phenotype ([Figure S1](#mmc1){ref-type="supplementary-material"}E), suggesting an additive effect. CM collected from human keratinocytes with extra centrosomes (HaCat.PLK4+DOX) also induced paracrine invasion of MCF10A cells, showing that this phenotype is not cell-type dependent ([Figure S1](#mmc1){ref-type="supplementary-material"}F and [Table S1](#mmc1){ref-type="supplementary-material"}).Figure 1Centrosome Amplification Induces Paracrine Invasion(A) Experimental flowchart.(B) Left, quantification of invasive structures. Right, normal and invasive 3D acini. White arrowheads indicate invasive protrusions. Scale bar: 20 μM.(C) Quantification of centrosome amplification.(D) Quantification of invasive structures.(E) Quantification of invasive structures.(F) Top, schematic representation of mammary organoids isolation and growth. Bottom, non-invasive and invasive mammary organoids. Scale bar: 20 μM.(G) Quantification of invasive organoids.(H) Images of zebrafish injected with cells with (+DOX) or without (−DOX) extra centrosomes (left) or co-injected +DOX/−DOX (right).(I) Incidence of invasive cells in zebrafish embryos. Number of injected fish −DOX = 121; +DOX = 103; and co-injection +/−DOX = 116.(J) Number of disseminated cells in the zebrafish tail. Error bars represent mean ± SEM.For all graphics, error bars represent mean ± SD from three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001; ns not significant.See also [Figure S1](#mmc1){ref-type="supplementary-material"}; [Videos S1](#mmc6){ref-type="supplementary-material"}, [S2](#mmc7){ref-type="supplementary-material"}, [S3](#mmc8){ref-type="supplementary-material"}, and [S4](#mmc9){ref-type="supplementary-material"}; [Table S1](#mmc1){ref-type="supplementary-material"}.

Video S1. Time-Lapse Phase Contrast Imaging MCF10A Acini in 3D Cultures at Day 4 after Treatment with CM Collected from MCF10A Cells with Normal Centrosome Number (−DOX), Related to Figure 1Images were acquired with a 10× objective over 44 hr, with images acquired every 10 min. Time is represented in hr:min:s.

Video S2. Time-Lapse Phase Contrast Imaging MCF10A Acini in 3D Cultures at Day 4 after Treatment with CM Collected from MCF10A Cells with Extra Centrosomes (+DOX), Related to Figure 1Images were acquired with a 10× objective over 44 hr, with images acquired every 10 min. Time is represented in hr:min:s.

Video S3. Time-Lapse Phase Contrast Imaging MCF10A Acini in 3D Cultures at Day 4 after Treatment with CM Collected from MCF10A Cells with Normal Centrosome Number (−DOX), Related to Figures 1 and S1Images were acquired with a 20× objective over 24 hr, with images acquired every 10 min. Time is represented in hr:min:s.

Video S4. Time Lapse Phase Contrast Imaging MCF10A Acini in 3D Cultures at Day 4 after Treatment with CM Collected from MCF10A Cells with Extra Centrosomes (+DOX), Related to Figures 1 and S1Images were acquired with a 20× objective over 24 hr, with images acquired every 10 min. Time is represented in hr:min:s.

We established that secretion of pro-invasive factors is a direct consequence of centrosome amplification and not due to unspecific effects of PLK4 overexpression or DOX treatment. First, depletion of SAS-6, a centrosomal protein essential for centrosome duplication ([@bib61], [@bib69]), in cells upon overexpression of PLK4 (+DOX) prevents centrosome amplification and paracrine invasion ([Figures 1](#fig1){ref-type="fig"}C and 1D). Second, CM collected from cells treated with DOX to induce the expression of a truncated PLK4 mutant (PLK4^1--608^) that does not induce centrosome amplification does not induce paracrine invasion ([Figure 1](#fig1){ref-type="fig"}E) ([@bib34]). Third, depletion of SAS-6 after centrosome amplification leads to loss of extra centrosomes and blocks the ability of these cells to induce paracrine invasion, demonstrating that this phenotype can be reversed by loss of extra centrosomes ([Figures S1](#mmc1){ref-type="supplementary-material"}G and S1H; [Table S1](#mmc1){ref-type="supplementary-material"}). Finally, increased paracrine invasion was observed in cells where centrosome amplification was generated by prolonged CDK1 inhibition, in the absence of DOX treatment ([Figure S1](#mmc1){ref-type="supplementary-material"}I and [Table S1](#mmc1){ref-type="supplementary-material"}) ([@bib46]).

We validated the ability of cells with extra centrosome to promote paracrine invasion in primary mouse mammary organoids that better recapitulate the architecture of the mammary gland. In this system, both myoepithelial cells (expressing α-SMA) and luminal cells become invasive upon treatment with CM from cells with extra centrosomes ([Figures 1](#fig1){ref-type="fig"}F and 1G). This type of invasion, in particular the collective invasive strands, resembles what has been described for invasive tumor organoids in 3D cultures ([@bib17]). Branching morphogenesis can also be observed in these conditions, but we did not quantify this phenotype as invasion ([Figure S1](#mmc1){ref-type="supplementary-material"}J).

To test if in the context of heterogeneous cell populations, cells with extra centrosomes could promote invasion of surrounding cells, we took advantage of the zebrafish model where co-injection of differentially labeled cells was performed. While injection of MCF10A cells with normal centrosome number (−DOX) does not induce an invasive phenotype, induction of centrosome amplification (+DOX) is sufficient to promote an invasive behavior *in vivo*, scored as the percentage of fish with cells that invaded into the tail (∼20%) ([Figures 1](#fig1){ref-type="fig"}H--1J). However, when control cells and cells with extra centrosomes are co-injected, non-invasive control cells become invasive (∼15%) ([Figures 1](#fig1){ref-type="fig"}H--1J). These results support a non-cell-autonomous role for centrosome amplification *in vivo*.

Induction of Paracrine Invasion Is Mediated by RTK Signaling {#sec2.2}
------------------------------------------------------------

To investigate the mechanisms by which CM from cells with extra centrosomes promoted invasion, we first tested if CM+DOX induced epithelial to mesenchymal transition (EMT) in MCF10A cells. We found that cells treated with CM+DOX did not undergo EMT, as assessed by the expression of epithelial (E-cadherin) and mesenchymal (N-cadherin and Vimentin) markers ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Next, we tested if the pro-invasive factors secreted by cells with extra centrosomes were permanently making them invasive by pre-treating MCF10A cells with CM for 48 hr before plating in 3D cultures (CM OFF) ([Figure 2](#fig2){ref-type="fig"}A). We found that pre-treatment with CM+DOX was not sufficient to induce an invasive phenotype ([Figure 2](#fig2){ref-type="fig"}A). Thus, signaling activation via secreted molecules is likely inducing paracrine invasion. To uncover the origin of the secreted pro-invasive factors, we filtered the CM using Vivaspin columns with a 5 kDa cutoff to separate larger molecules (e.g., proteins) from small molecules (e.g., metabolites). We found that only the larger fraction (\>5 kDa) was able to induce invasion ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). Treatment of the CM+DOX with trypsin-coated beads completely abolished the invasive phenotype, further supporting that it is a protein-mediated phenotype ([Figures 2](#fig2){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}B).Figure 2Induction of Paracrine Invasion Is Mediated by RTK Signaling(A) Left, schematic representation of the different CM treatments. Right, quantification of invasive structures.(B) Quantification of invasive structures.(C) Fold increase in RTK phosphorylation in MCF10A cells after incubation with CM+DOX.(D) Left, quantification of invasive structures with or without HER2 (Trastuzumab, 40 μg/mL) and c-Met (PHA-66752, 1 μM) inhibitors. Right, acinar structures. Red arrowheads indicate invasive acini. Scale bar: 40 μM.For all graphics, error bars represent mean ± SD from three independent experiments. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001; ns not significant.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

To dissect the signaling pathways activated by CM+DOX, we performed a phospho-receptor tyrosine kinase (RTK) array in MCF10A cells treated with CM collected from control (CM−DOX) and cells with extra centrosomes (CM+DOX). Analyses of the phospho-RTK array revealed that EGFR, HER2 (ErbB2), and c-Met (HGFR) signaling were increased in cells treated with CM+DOX, although only HER2 was significantly increased ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}D). Addition of the HER2 inhibitor (Trastuzumab), but not the c-Met inhibitor (PHA-66752) to the recipient cells, prevented paracrine invasion induced by the CM+DOX, without affecting acinar growth ([Figures 2](#fig2){ref-type="fig"}D, [S2](#mmc1){ref-type="supplementary-material"}E, and S2F). Our data demonstrate that activation of HER2 signaling in the recipient cells drives non-cell-autonomous invasion. Because EGF signaling is essential for MCF10A proliferation, it remains undetermined if EGFR is important for the invasive phenotype observed ([Figures S2](#mmc1){ref-type="supplementary-material"}G and S2H).

Secretome Analysis Reveals Differential Protein Secretion in Cells with Amplified Centrosomes {#sec2.3}
---------------------------------------------------------------------------------------------

To identify the secreted proteins important for paracrine invasion, we performed label-free mass spectrometry on the CM−DOX and CM+DOX ([Figure 3](#fig3){ref-type="fig"}A). CM was collected 16 hr after incubation with serum-free medium to prevent cell death, as assessed by the presence of the enzyme lactate dehydrogenase (LDH) in the media ([Figure S2](#mmc1){ref-type="supplementary-material"}I). Proteomic analyses uncovered changes (log2-fold \> 1.5) in the secretomes of cells with and without centrosome amplification ([Figure 3](#fig3){ref-type="fig"}B and [Table S2](#mmc2){ref-type="supplementary-material"}), demonstrating the existence of an extra centrosomes-associated secretory phenotype (ECASP). Similar to other secretomic studies ([@bib1]), qualification of proteins differentially present in the CM revealed that approximately 25% of those are assigned to the extracellular compartment ([Figure 3](#fig3){ref-type="fig"}C). Further analyses of this compartment suggested that many of the identified secreted proteins have been previously associated with extracellular vesicles, particularly exosomes (Exos) ([Figure 3](#fig3){ref-type="fig"}C). However, while fractions enriched for microvesicles (MVs) or Exos did not significantly promote invasion, CM depleted of extracellular vesicles (MVs and Exos) retained the potential to induce invasion ([Figure S2](#mmc1){ref-type="supplementary-material"}J). To complement our secretomic analyses and exclude proteins associated with MVs and Exos, we performed a quantitative membrane-based protein array (Human XL Oncology Array) of the collected CM ([Figures 3](#fig3){ref-type="fig"}A and 3D). Short and long exposures of the membranes revealed proteins significantly secreted by cells with amplified centrosome number ([Figures 3](#fig3){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}K). Ingenuity pathway analysis (IPA) of the secreted proteins identified by mass spectrometry and/or protein array demonstrated that many have been previously linked to cancer invasion and migration ([Figure 3](#fig3){ref-type="fig"}E and [Table S3](#mmc3){ref-type="supplementary-material"}). From those, we selected 38 proteins based on fold change and function in cancer ([Table S4](#mmc4){ref-type="supplementary-material"}) and performed a small-scale small interfering RNA (siRNA) screen in cells with extra centrosomes to identify the secreted pro-invasive proteins ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). qRT-PCR to assess knockdown efficiency indicated that 3 out of 38 proteins were not depleted, and therefore they were not pursued further ([Figure S3](#mmc1){ref-type="supplementary-material"}C). We identified 11 proteins that upon depletion decreased paracrine invasion by at least 1 standard deviation (SD) of the siRNA control condition (∼5%) ([Figure 3](#fig3){ref-type="fig"}F, green circles). The decrease in paracrine invasion was independent of cell viability and proliferation rates ([Figure S3](#mmc1){ref-type="supplementary-material"}D). We further validated some of the hits that have been previously associated with invasion using independent siRNA pool sets: Interleukin-8 (IL-8), Mesothelin (MSLN), Angiopoietin-like protein 4 (ANGPTL4), SerpinE1 (PAI), and Growth-Factor Differentiation 15 (GDF-15) ([Figures 3](#fig3){ref-type="fig"}G and [S3](#mmc1){ref-type="supplementary-material"}E) and confirmed their increased secretion by ELISA ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4E). Apart from GDF-15, increased secretion of these factors at 48 hr cannot be explained by increased mRNA levels ([Figure S4](#mmc1){ref-type="supplementary-material"}F). One of our top hits, IL-8, also known as C-X-C motif ligand 8 (CXCL8), is a pro-inflammatory chemokine with known roles in promoting cancer cell invasion ([@bib77]). IL-8 signaling has also been shown to induce transactivation of HER2 ([@bib66]), which is important for centrosome amplification-induced paracrine invasion ([Figure 2](#fig2){ref-type="fig"}D). Deconvoluted siRNA pools for IL-8 confirmed its role in paracrine invasion ([Figure S4](#mmc1){ref-type="supplementary-material"}G). Furthermore, while recombinant IL-8 was not sufficient to induce invasion when added to CM−DOX, it fully restored the invasive capacity of the CM+DOX collected from cells depleted of IL-8 ([Figures S4](#mmc1){ref-type="supplementary-material"}H and S4I). Taken together, our data suggest that paracrine invasion induced by extra centrosomes is likely promoted by a combination of secreted factors, with IL-8 playing a crucial role.Figure 3Secretome Analysis Reveals Differential Protein Secretion in Cells with Amplified Centrosomes(A) Experimental flowchart.(B) Log~2~-fold changes in protein abundance in the CM of cells with extra centrosomes (+DOX). Red circles indicate changes \>1.5-fold difference.(C) Pie charts represent the cellular localization of the proteins increased in CM+DOX. See [STAR Methods](#sec4){ref-type="sec"} for details.(D) Fold change of secreted proteins in CM+DOX using protein array.(E) IPA classification of the extracellular secreted proteins identified by mass spectrometry and protein arrays.(F) Quantification of invasive structures after siRNA depletion.(G) Left, validation of specific positive hits identified in (F). Right, acinar structures. Red arrowheads indicate invasive acini. For all graphics, error bars represent mean ± SD from three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01. Scale bar: 40 μM.See also [Figure S3](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.

Secreted IL-8 Is Crucial for Paracrine Invasion through HER2 Activation {#sec2.4}
-----------------------------------------------------------------------

To investigate the mechanisms by which IL-8 could be promoting paracrine invasion, we inhibited IL-8 G-protein-coupled receptors CXCR1 and CXCR2 in the recipient cells using specific inhibitors ([@bib12], [@bib15]). While the CXCR1/2 allosteric inhibitor Reparixin only partially prevented invasion, inhibition of CXCR1/2 with SCH563705 (potently inhibits CXCR2) abolished paracrine invasion without affecting 3D growth ([Figure 4](#fig4){ref-type="fig"}A). This was confirmed by siRNA depletion of CXCR2 in the recipient cells ([Figures 4](#fig4){ref-type="fig"}B and 4C). Importantly, CXCR2 depletion in cells with extra centrosomes did not prevent direct invasion, although we did observe a consistent decrease in the invasive phenotype ([Figure 4](#fig4){ref-type="fig"}C). These results further support that the pathways that underline direct and paracrine invasion are distinct. We confirmed the importance of IL-8 signaling in this process using mouse mammary organoids. Although mice do not express IL-8, they express CXCR2 that binds to human IL-8 ([@bib65]). Mammary organoids generated from mice knockout for CXCR2 (CXCR2^−/−^) did not show increased invasion when treated with CM+DOX ([Figures 4](#fig4){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}J). Co-injection experiments in zebrafish demonstrated that, although depletion of CXCR2 in control MCF10A cells (−DOX) did not abolish paracrine invasion ([Figure S4](#mmc1){ref-type="supplementary-material"}K), it significantly decreased the number of control cells that co-invaded with cells with extra centrosomes (+DOX), indicating that IL-8 signaling plays an important role in paracrine invasion *in vivo* ([Figure 4](#fig4){ref-type="fig"}E).Figure 4Secreted IL-8 Is Crucial for Paracrine Invasion through Her2 Activation(A) Left, quantification of invasive structures with and without the CXCR1/2 inhibitors Reparixin (100 nM) and SCH563705 (100 nM). Right, acinar structures. Red arrowheads indicate invasive acini. Scale bar: 40 μM.(B) Experimental flowchart.(C) Quantification of invasive structures upon CXCR2 depletion in cells with extra centrosomes (direct) or incubated with CM+DOX (paracrine).(D) Left, quantification of invasive mammary organoids from WT or CXCR2^−/−^ mice. Right, non-invasive and invasive mammary organoids. Scale bar: 20 μM.(E) Left, ratio of disseminated cells in co-injection experiments. Right, zebrafish embryos co-injected with cells with (+DOX, red) and without centrosome amplification (−DOX, green). Number of injected fish co-injection control siRNA = 71; co-injection CXCR2 siRNA = 121.(F) Top, levels of p-Erk1/2 and total Erk1/2 in cells. Bottom, ratio of phospho/total Erk1/2. B, basal conditions; S, serum starved cells; +M, serum starved cells after incubation with fresh medium.(G) Left, quantification of invasive structures with or without Erk1/2 inhibitor (PD98059, 20 μM). Right, acinar structures. Red arrowheads indicate invasive acini. Scale bar: 40 μM.(H) Left, quantification of invasive structures with and without Src inhibitor (PP2, 5 μM). Right, acinar structures. Red arrowheads indicate invasive acini. Scale bar: 40 μM.For all graphics, error bars represent mean ± SD from three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; ns not significant.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Because CM+DOX activates HER2 ([Figure 2](#fig2){ref-type="fig"}C), we decided to test if HER2 activation requires IL-8 signaling. To do so, we assessed Erk1/2 phosphorylation, as a consequence of HER2 activation, in recipient cells treated with CM+DOX. We found that, when compared to CM−DOX, CM+DOX induces a 2-fold increase in Erk1/2 activation. Moreover, pre-treating the recipient cells with HER2 or CXCR1/2 inhibitors significantly decreased Erk1/2 activation ([Figure 4](#fig4){ref-type="fig"}F). Similar to HER2 inhibition, chemical inhibition of Erk1/2 and Src, important for HER2 transactivation mediated by IL-8 ([@bib66]), in the recipient cells also prevented invasion induced by CM+DOX ([Figures 4](#fig4){ref-type="fig"}G and 4H). Taken together, our results show that Erk1/2 activation is important for paracrine invasion and requires activation of the IL-8 receptor.

Centrosome Amplification Induces an Early Stress Response that Leads to Altered Secretion {#sec2.5}
-----------------------------------------------------------------------------------------

Altered protein secretion in senescent cells, known as the senescence-associated secretory phenotype (SASP), was previously shown to lead to IL-8 secretion ([@bib19]). Early secretory phenotype observed in cells with extra centrosomes is unlikely to be a consequence of senescence since it is induced very early (48 hr after induction of extra centrosomes), and high levels of proliferating cells can be observed even after 6 days, as measured by ki67 staining ([Figure 5](#fig5){ref-type="fig"}A). However, the percentage of dividing cells with extra centrosomes is lower at day 6 ([Table S1](#mmc1){ref-type="supplementary-material"}). Thus, it is possible that this early response to centrosome amplification could culminate in a senescence phenotype. To test this idea, we performed β-galactosidase staining in cells 6 and 10 days after induction of centrosome amplification. In contrast to cells treated with the DNA-damage-inducing drug Doxorubicin (DoxoR) ([@bib8]), centrosome amplification in MCF10A cells was not sufficient to drive a strong senescence phenotype ([Figures 5](#fig5){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}A). However, our data suggest that these cells display senescence-like features. First, centrosome amplification increases p53 and p21 protein levels ([@bib37]) ([Figure S5](#mmc1){ref-type="supplementary-material"}B), which is also observed in senescent cells ([@bib79]). Second, the comparison of the mRNA levels of the identified pro-invasive factors at day 6 revealed a similar trend between senescent cells (DoxoR treated) and cells with extra centrosomes, although overall senescent cells exhibit a stronger response ([Figure S5](#mmc1){ref-type="supplementary-material"}C). In addition, senescent cells exhibit a similar paracrine invasive behavior as centrosome amplification, although they exhibit higher levels of secreted pro-invasive factors ([Figures 5](#fig5){ref-type="fig"}C, 5D, and [S5](#mmc1){ref-type="supplementary-material"}G). This partial senescence-like response could be a consequence of the lack of p16 in MCF10A cells ([@bib9]), since both p16 and p53 are important mediators of senescence ([@bib79]). To test if centrosome amplification was sufficient to induce senescence in cells with intact p16 and p53, we used human retinal pigment epithelium (RPE-1) and human primary breast fibroblast (BF) cell lines. Although RPE-1 were negative for β-galactosidase staining, centrosome amplification was sufficient to induce an enlarged cell morphology phenotype in ∼30% of the cells consistent with senescence after 7 days ([Figure 5](#fig5){ref-type="fig"}E and [Table S1](#mmc1){ref-type="supplementary-material"}). Similar results were observed in BF cells as scored by β-galactosidase staining ([Figure S5](#mmc1){ref-type="supplementary-material"}D and [Table S1](#mmc1){ref-type="supplementary-material"}). Notably, the levels of β-galactosidase were lower than that of BF cells treated with DoxoR, suggesting that extra centrosomes might elicit a different or less strong senescent response. We also assessed double-stranded DNA (dsDNA) breaks, as measured by γH2AX foci, and found that while there is a significant increase in cells with extra centrosomes, only 1.7% and 11.3% of MCF10A and RPE-1 cells, respectively, show more than 5 DNA damage foci ([Figure 5](#fig5){ref-type="fig"}F). This contrasts with DoxoR-induced senescent cells where ∼99% of cells have more than 5 DNA damage foci ([Figure 5](#fig5){ref-type="fig"}F). Furthermore, while enlarged nuclei in senescent cells induced by DoxoR correlate with increased DNA damage foci, the same was not observed in cells with extra centrosomes ([Figures S5](#mmc1){ref-type="supplementary-material"}E and S5F). To further understand the association of ECASP with senescence, we compared the secretion of well-established SASP components ([@bib19]), including IL-8 (our positive control), IL-6, uPar, MIP-3α, MCP-1, GRO -a, -b, -c, and IL-1β, in cells with extra centrosomes or treated with DoxoR over time (48 hr and 7 days). At 48 hr, we did not observe a strong SASP, and only secretion of IL-6 and IL-8 was observed ([Figures 5](#fig5){ref-type="fig"}G and 5H). At 7 days, DoxoR-induced senescent cells displayed a stronger SASP than cells with extra centrosomes in both MCF10A and RPE-1 cells ([Figures 5](#fig5){ref-type="fig"}G and 5H). In RPE-1 cells, centrosome amplification and DoxoR-treated cells show a similar pattern of secreted SASP components. By contrast, MCF10A cells with extra centrosomes only show increased secretion of IL-6 and IL-8 even after 7 days ([Figures 5](#fig5){ref-type="fig"}G, 5H, and [S5](#mmc1){ref-type="supplementary-material"}H). Taken together, these results suggest that centrosome amplification can promote senescence and SASP in some cells. Similar results on a SASP induced by centrosome amplification have also been observed by others (D. Pellman, personal communication). Importantly, the early secretory phenotype we observed at 48 hr does not require cells to become senescent, as these still display high levels of proliferation. Instead, we hypothesized that this early secretory phenotype is caused by an early stress response, which could lead to senescence. Further supporting this idea, secretion of HMGB1, which is secreted very early after a senescence-induced stimulus and before the development of SASP ([@bib21]), is also observed 48 hr after induction of extra centrosomes ([Figure 5](#fig5){ref-type="fig"}I). This stress response requires p53, since short-term depletion of p53 abolished paracrine invasion and decreased IL-8 secretion ([Figures 5](#fig5){ref-type="fig"}J, 5K, and [S5](#mmc1){ref-type="supplementary-material"}I). This is not due to cell-cycle arrest mediated by p53 since p21 depletion did not prevent IL-8 secretion and paracrine invasion ([Figures S5](#mmc1){ref-type="supplementary-material"}J--S5L). Taken together, our results suggest that a stress response downstream of extra centrosomes alters secretion that in some conditions can develop into a SASP.Figure 5Centrosome Amplification Induces an Early Stress Response that Leads to Altered Secretion(A) Left, quantification of Ki67 positive cells. Right, cells stained for Ki67. Scale bar: 40 μM.(B) Left, cells stained for β-galactosidase (blue). Right, quantification of β-galactosidase positive cells after 6 days. Scale bar: 40 μM.(C) Relative IL-8 secretion (fold, ng/cell) in cells with extra centrosomes (Left) or treated with DoxoR (Right).(D) Quantification of invasive structures.(E) Left, cells stained for β-galactosidase (blue). Right, quantification of senescence in RPE-1.PLK4 cells. Note that senescence was assessed by enlarged morphology (purple arrowheads). Scale bar: 40 μM.(F) Left, quantification of γH2AX foci. Right, cells were stained for γH2AX. L, large nuclei. Number of cells MCF10A.PLK4 −DOX = 469; +DOX = 466; and RPE-1.PLK4 −DOX = 155; +DOX = 115; +DoxoR = 84. Scale bar: 20 μM.(G and H) (G) Fold change of secreted SASP components in MCF10A and (H) RPE-1 cells.(I) HMGB1 secretion after 48 hr.(J) IL-8 secretion after p53 depletion (48 hr).(K) Quantification of invasive structures.Graphic in (G) represents 4 independent experiments; for all other graphics, error bars represent mean ± SD from three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001; ns, not significant.See also [Figure S5](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.

Increased ROS Levels in Cells with Extra Centrosomes Drive Secretion {#sec2.6}
--------------------------------------------------------------------

Recent work showed that induction of highly abnormal karyotypes leads to senescence and secretion of pro-inflammatory cytokines ([@bib62]). In our conditions, induction of centrosome amplification for 48 hr leads to low levels of chromosome missegregation ([@bib31]). We found that depletion of MCAK, which induces similar levels of aneuploidy to centrosome amplification ([@bib31]), does not lead to paracrine invasion and IL-8 secretion ([Figures S5](#mmc1){ref-type="supplementary-material"}M--S5O). One common denominator between IL-8 secretion and senescence is increased reactive oxygen species (ROS) levels ([@bib27], [@bib33]). The levels of ROS can dictate the cellular response: high levels lead to senescence and apoptosis, whereas milder levels are associated with tumorigenesis ([@bib33]). Thus, we postulated that increased levels of ROS in cells with extra centrosomes could alter secretion and, depending on the cellular context, also induce senescence. To test this, we measured ROS levels in cells with extra centrosomes using the fluorogenic dye DCFDA. We found that induction of centrosome amplification induces a 1.5-fold increase in ROS, which can be prevented by treating cells with the antioxidant N-acetyl cysteine (NAC). A similar response was observed in cells treated with DoxoR for 3 hr ([Figure 6](#fig6){ref-type="fig"}A). This was further confirmed by quantifying the levels of reduced Glutathione, which is decreased in response to ROS (∼2-fold) ([Figure 6](#fig6){ref-type="fig"}B). Induction of extra centrosomes leads to the nuclear accumulation of the nuclear factor erythroid 2-related factor 2 (NRF2), a transcription factor that is stabilized and translocates into the nucleus in response to ROS ([Figure 6](#fig6){ref-type="fig"}C) ([@bib33]). Consistently, gene expression analysis of MCF10A.PLK4 with extra centrosomes revealed an early transcriptional response involving the overexpression of genes that control intracellular ROS, some of which are downstream of NRF2 ([Figure 6](#fig6){ref-type="fig"}D and [Table S5](#mmc5){ref-type="supplementary-material"}).Figure 6Increased ROS Levels in Cells with Extra Centrosomes Drive Secretion(A and B) (A) Levels of intracellular ROS using DCFDA or (B) by measuring the ratio of GSH/GSSG (48 hr).(C) NRF2 protein levels in the cytosolic and nuclear fractions.(D) Gene expression profile of cells with extra centrosomes (48 hr) compared to an NRF2 (NFE2L2)-induced gene-set signature.(E) IL-8 secretion in after NAC treatment.(F) Quantification of invasive structures.(G) Left, cells stained for β-galactosidase (blue). Right, quantification of β-galactosidase positive cells. Scale bar: 40 μM.(H) Left, quantification of γH2AX foci. Right, cells were stained for DNA (green) and γH2AX (magenta). L, large nuclei. Number of cells MCF10A.PLK4 −DOX = 469; −DOX+H2O2 = 518; +DOX = 466; +DOX+H2O2 = 377. Scale bar: 20 μM.(I) Quantification of invasive structures.(J) Ratio of GSH/GSSG.(K) IL-8 secretion in cells treated with apocynin.(L) Quantification of invasive structures. For all graphics error bars, represent mean ± SD from three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001; ns not significant.See also [Figure S6](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.

We uncovered that ROS is a key player in the paracrine invasive phenotype mediated by extra centrosomes. Treatment of cells with NAC prevented both IL-8 secretion and paracrine invasion, without affecting the levels of centrosome amplification ([Figures 6](#fig6){ref-type="fig"}E and 6F; [Table S1](#mmc1){ref-type="supplementary-material"}). To test whether the lack of a classical senescent phenotype in MCF10A cells could be overcome by further increasing ROS, we treated cells with different doses of the ROS-inducing agent H2O2. Indeed, H2O2 concentrations that did not induce senescence in control cells were able to induce a stronger p53 response and promote senescence in cells with extra centrosomes ([Figures 6](#fig6){ref-type="fig"}G and [S6](#mmc1){ref-type="supplementary-material"}A--S6C). This is consistent with increased DNA damage foci and a decrease in cell proliferation and dividing cells with extra centrosomes ([Figures 6](#fig6){ref-type="fig"}H, [S6](#mmc1){ref-type="supplementary-material"}D, and S6E; [Table S1](#mmc1){ref-type="supplementary-material"}). Moreover, 100 μM H2O2 was sufficient to promote IL-8 secretion and paracrine invasion, further supporting a role for ROS in this process ([Figures S6](#mmc1){ref-type="supplementary-material"}F and S6G). Interestingly, reducing ROS levels with NAC also affected the secretion of ANGPTL4, GDF-15, and PAI, while MSN was still secreted at similar levels ([Figures S6](#mmc1){ref-type="supplementary-material"}H--S6K). Because NAC prevents paracrine invasion, we tested if a combination of ROS-mediated secreted factors was sufficient to drive invasion. In contrast to the addition of recombinant IL-8, ANGPTL4, or GDF-15 alone, the combination of these three factors to CM−DOX was sufficient to promote paracrine invasion ([Figure 6](#fig6){ref-type="fig"}I), suggesting that ROS-mediated secretion plays crucial roles in non-cell-autonomous invasion.

Intracellular ROS can originate in the cytoplasm or mitochondria ([@bib7], [@bib52]). Inhibition of NADPH oxidases (NOXs), which drives cytoplasmic ROS, with apocynin decreased ROS levels, prevented IL-8 secretion and paracrine invasion in cells with extra centrosomes ([Figures 6](#fig6){ref-type="fig"}J--6L). This was confirmed by siRNA depletion of p22^phox^, a common subunit of the NOX1-4 complexes ([Figure S7](#mmc1){ref-type="supplementary-material"}A). By contrast, inhibition of mitochondrial ROS with MitoTempo did not prevent paracrine invasion, and centrosome amplification did not increase mitochondrial ROS, as assessed using the fluorogenic dye MitoSox ([Figures S7](#mmc1){ref-type="supplementary-material"}B--S7D).

RAC1 activity is increased in cells with extra centrosomes ([@bib31]) and can activate NOX to increase ROS production ([@bib7]); therefore, we tested whether RAC1 activity was important for ROS generation. To do so, we used a RAC1 inhibitor that we have previously shown to prevent increased RAC1 activity in response to centrosome amplification ([@bib31]). In this condition, RAC1 inhibition did not prevent increased ROS, and as a consequence, these cells were able to secrete IL-8 ([Figures S7](#mmc1){ref-type="supplementary-material"}E and S7F). As RAC1 is important for the formation of invasive protrusions, we tested if the CM+DOX collected from D cells treated with RAC1 inhibitor still had the potential to induce invasion, after using Vivaspin columns to remove the inhibitor from the CM ([Figure S7](#mmc1){ref-type="supplementary-material"}G). Whereas CM+DOX containing the RAC1 inhibitor prevented the formation of invasive protrusions, after removal of the inhibitor CM+DOX still retained the ability to induce paracrine invasion ([Figure S7](#mmc1){ref-type="supplementary-material"}H). Thus, increased RAC1 activity is not necessary for the early secretion of pro-invasive factors.

We postulated that increased ROS could be a consequence of p53 stabilization since p53 plays important roles in redox homeostasis ([@bib43]), and we found it to be important for paracrine invasion ([Figure 5](#fig5){ref-type="fig"}K). The role of p53 in modulating cellular ROS is complex. While p53 can be downstream of high levels of ROS, p53 activation has also been shown to promote ROS, which is important to drive senescence or apoptosis ([@bib74]). NAC treatment did not block p53 stabilization in cells with extra centrosomes, suggesting that p53 activation is not mediated by ROS ([Figure S7](#mmc1){ref-type="supplementary-material"}I). Furthermore, we found that induction of p53 stabilization for 48 hr using Nutlin-3, an inhibitor of the p53 negative regulator MDM2, is sufficient to induce ROS, IL-8 secretion, and paracrine invasion in normal MCF10A cells, independently of centrosome amplification ([Figures S7](#mmc1){ref-type="supplementary-material"}J--S7M; [Table S1](#mmc1){ref-type="supplementary-material"}). Nutlin-3 treatment also induces HMGB1 secretion, similarly to centrosome amplification ([Figure S7](#mmc1){ref-type="supplementary-material"}N). Altogether, our results suggest that p53-mediated ROS production leads to an early secretory response in cells with extra centrosomes that promotes non-cell-autonomous invasion.

Centrosome Amplification in Breast Cancer Mediates Paracrine Invasion and Is Associated with IL-8 Secretion {#sec2.7}
-----------------------------------------------------------------------------------------------------------

To establish the relevance of our findings in cancer, we next tested whether CM collected from cells with supernumerary centrosomes could induce invasion in organoid cultures of primary cells from mouse tumors derived from Polyomavirus middle T oncogene (PyMT) ([@bib55]). We found that CM+DOX was sufficient to increase invasion of tumor organoids after 4 and 7 days' incubation. This was accompanied by an increase in the number of tubular structures particularly at day 7 ([Figures 7](#fig7){ref-type="fig"}A and 7B). Tubular structures incubated with CM+DOX display an increase in the area and number of branches. This was not due to increased proliferation since round organoids do not show these differences ([Figures 7](#fig7){ref-type="fig"}C and 7D). Branches are locally regulated invasive epithelial buds essential for formation of the mammary gland ([@bib68]); thus, the increase in tubular organoids and branching further supports a role for CM+DOX in promoting invasion. The formation of branches is controlled via paracrine interactions and requires HER2 signaling ([@bib68]), similar to paracrine-induced invasion by cells with extra centrosomes.Figure 7Centrosome Amplification in Breast Cancer Mediates Paracrine Invasion and Is Associated with IL-8 Secretion(A) Quantification of round invasive and tubular structures in PyMT-derived tumor organoids.(B) Tumor organoids. Scale bar: 20 μM.(C) Area and branching of the tumor organoids. Error bars represent mean ± SEM.(D) PyMT tubular organoids. Scale bar: 100 μM.(E) Levels of centrosome amplification and breast cancer subtype.(F) mRNA expression levels of pro-invasive factors.(G) Quantification of invasive structures.(H) Schematic representation of how centrosome amplification promotes secretion and paracrine invasion.Unless specified, for all graphics, error bars represent mean ± SD from three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01; ns, not significant.See also [Figure S7](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.

We found that CM collected from breast cancer cell lines with extra centrosomes (MDA-231 and BT-549) was also able to increase paracrine invasion of MCF10A cells, suggesting that this effect is not restricted to non-transformed cells. This further emphasizes that non-cell-autonomous invasion induced by centrosome amplification does not require cells to be senescent ([Figures 7](#fig7){ref-type="fig"}E and [S7](#mmc1){ref-type="supplementary-material"}O). Using the Cancer Cell Line Encyclopedia (CCLE) database, we found a correlation between centrosome amplification and the expression of the secreted pro-invasive factors, excluding GDF-15, in a panel of breast cancer cell lines ([Figures 7](#fig7){ref-type="fig"}E and 7F), which we previously characterized for centrosome amplification ([@bib60]). Importantly, induction of centrosome amplification in the breast cancer cells lines MCF-7 (p53 WT) and HCC-1954 (p53 mutant), which are of luminal and basal origin, respectively, was also sufficient to induce paracrine invasion in the recipient MCF10A cells ([Figure 7](#fig7){ref-type="fig"}G and [Table S1](#mmc1){ref-type="supplementary-material"}). Thus, centrosome amplification-induced paracrine invasion is independent of the breast cancer subtype and can occur in the presence of at least some p53 mutations. In the case of HCC-1954 harboring the missense c.488A\>G p53 mutation, increased ROS was observed upon induction of extra centrosomes ([Figure S7](#mmc1){ref-type="supplementary-material"}P). Therefore, the presence of extra centrosomes elicits a similar non-cell-autonomous phenotype in non-transformed and cancer cells. Taken together, we propose that a stress response downstream of extra centrosomes leads to the secretion of proteins, partly mediated by increased ROS, that promote an invasive behavior in the surrounding cells ([Figure 7](#fig7){ref-type="fig"}H).

Discussion {#sec3}
==========

Our study establishes that the impact of extra centrosomes in tumors goes beyond altering the biology of cells that carry this abnormality by promoting non-cell-autonomous invasion. Structural centrosomal abnormalities have been recently shown to play non-cell-autonomous roles by changing the biomechanical properties of the epithelium leading to the budding of mitotic cells ([@bib29]). Here, we show that non-cell-autonomous invasion promoted by centrosome amplification is mediated by a secretory response that culminates with the secretion of multiple pro-invasive factors, including IL-8, ANGPTL4, PAI, MSN, and GDF-15, previously implicated in cancer invasion ([@bib14], [@bib24], [@bib72], [@bib76], [@bib77]). The combination of some of these factors (IL-8, ANGPTL4, and GDF-15) was sufficient to induce paracrine invasion, suggesting that multiple pathways are involved. One of the pathways important for this process is HER2 signaling, which can be activated by Src kinase downstream of the IL-8-CXCR1/2 axis ([@bib66]). It is still unclear which pathways downstream of GDF-15 and ANGPTL4 are involved. In cancer, the cognitive receptor for GDF-15 is unknown; however, the C-terminal fragment of ANGPTL4, used in this study, can bind and activate β1 and β5 integrins, which could aid invasion ([@bib32]). In breast cancer cells, centrosome amplification drives paracrine invasion and is correlated with the expression of pro-invasive factors, highlighting the importance of these findings in cancer.

IL-8, a recognized pro-inflammatory chemokine, is overexpressed in tumors and plays roles in invasion, proliferation, and survival of tumor cells, as well as in angiogenesis and immune infiltration ([@bib44], [@bib77]). Consequently, elevated serum levels of IL-8 are associated with distant metastasis and considered an unfavorable prognostic factor in breast cancer ([@bib5], [@bib50]). How IL-8 expression and secretion is regulated in tumors is not completely understood. IL-8 regulation occurs mostly at the transcriptional level, and its expression is induced by inflammatory signals (e.g., tumor necrosis factor α, IL-1β), environmental stresses (e.g., hypoxia) and exposure to chemotherapy agents (e.g., 5-fluorouracil, paclitaxel) ([@bib77]). We found that centrosome amplification can lead to increased IL-8 expression. Moreover, our data suggest that early IL-8 secretion is induced by NOX-mediated ROS production. These findings are reminiscent of what has been observed in neutrophils in which rapid release of IL-8 was shown to be a consequence of NOX-induced ROS ([@bib36]). Our work suggests that the presence of extra centrosomes could regulate IL-8 production and/or secretion in tumors. Supporting this idea, we found that IL-8 expression correlates with centrosome amplification in breast cancer cell lines. Moreover, breast cancer stem cells with high levels of the ubiquitin-specific protease 44 (USP44) display centrosome amplification and increased IL-8 expression, which promotes vascularization and predicts aggressive behavior ([@bib45]).

Generation of ROS is vital to redox signaling. To prevent oxidative stress, ROS levels are exquisitely balanced by pro- and antioxidants ([@bib73]). This balance is often perturbed in cancer, leading to overall higher ROS levels. However, because high levels of ROS are toxic, tumors develop strong antioxidant mechanisms to prevent cell death ([@bib35]). NRF2, one of the major regulators of antioxidant responses, is often stabilized in response to oncogenes such as K-RAS and MYC and is essential for tumor detoxification and growth ([@bib22], [@bib67]). We demonstrate that NFR2 is also stabilized and accumulates in the nucleus where it drives an antioxidant transcriptional response downstream of centrosome amplification. This could be important to prevent ROS-induced damage and a vital adaptation mechanism to centrosome amplification. ROS increase in cells with amplified centrosomes appears to be mediated by p53 stabilization, since p53 depletion decreases ROS-mediated IL-8 secretion and prevents paracrine invasion. This is consistent with the central role of p53 in ROS production ([@bib43]). p53 overexpression was shown to increase ROS levels via transactivation of several ROS-generating enzymes such as NQO1 as well as p67^phox^, an activating subunit of NOX2 complex, while suppressing the expression of antioxidant genes ([@bib23], [@bib38], [@bib57], [@bib75]).

At higher levels, ROS can mediate senescence and apoptosis downstream of p53 ([@bib74], [@bib79]). Indeed, centrosome amplification can induce senescence in a fraction of RPE-1 and BF cells. However, in MCF10A cells, centrosome amplification only induced a senescence-like response. This is consistent with our findings demonstrating that MCF10A cells do not develop a strong SASP. This further supports that the early secretory response we observe in these cells precedes senescence. The differences in response to centrosome amplification fit with the idea that the type and extent of the p53-inducing stress and/or cellular context determines the outcome of ROS production ([@bib39]). Thus, it is plausible that the response to ROS downstream of extra centrosomes varies among cell types, and it will be interesting to investigate if this would culminate with different secretory signatures. It also suggests that only cells with robust antioxidant mechanisms are able to resist centrosome amplification-induced senescence. Intriguingly, both in tumors and liver, where strong antioxidant mechanisms are important for cell survival, accumulation of cells with extra centrosomes can be observed without induction of a senescence phenotype ([@bib25], [@bib33]), ([@bib63]). We propose that in order for these cells to efficiently proliferate, they require effective mechanisms to prevent ROS-induced senescence. Since cellular senescence can act as a safeguard against tumorigenesis, it is possible that escaping from ROS-induced senescence could allow cells with extra centrosomes to become tumorigenic while affecting the surrounding cells via paracrine signaling.

Recent work showed that supernumerary centrosomes are sufficient to drive tumorigenesis in mice ([@bib42]). Although these tumors show recurrent aneuploidies, the role of aneuploidy in the initiation of extra centrosome-derived tumors remains elusive. Our work, demonstrating that centrosome amplification induces ROS production, suggests that ROS signaling and DNA mutagenesis could play a role in tumor initiation. These findings also highlight ROS as a potential weakness of cells with extra centrosomes, and perhaps therapies that specifically target antioxidant pathways, currently under clinical trials, could be critical in targeting these cells ([@bib33]). Indeed, we found that low doses of H2O2 decrease the proliferation of cells with extra centrosomes. The demonstration that centrosome amplification alters protein secretion indicates that cells carrying extra centrosomes have the ability to change the surrounding tumor cells as well as the tumor microenvironment. Hence, as the therapeutic potential of targeting subset of cells with extra centrosomes within a tumor remains uncertain ([@bib30]), our findings raise the exciting possibility that targeting these cells could have a bigger impact in the clinic than anticipated. The notion that cells with extra centrosomes could be a source of pro-tumorigenic factors, such as IL-8, indicates that tumors could benefit from having cells with extra centrosomes. We postulate that these non-cell-autonomous advantageous effects could help to explain why cells with amplified centrosomes, despite their fitness cost, are kept during tumor evolution.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rabbit Alexa-conjugated A488Molecular Probes\#A11008; RRID: [AB_143165](nif-antibody:AB_143165){#interref45}Mouse Alexa-conjugated A568Molecular Probes\#A11011; RRID: [AB_143157](nif-antibody:AB_143157){#interref50}Mouse Ki67 Alexa-conjugated A488BD Biosciences\#561165; RRID: [AB_10611866](nif-antibody:AB_10611866){#interref55}Mouse Laminin V Alexa-conjugated A488Millipore\#MAB19562X; RRID: [AB_570380](nif-antibody:AB_570380){#interref60}Mouse α-tubulinSigma-Aldrich\#T9026; RRID: [AB_477593](nif-antibody:AB_477593){#interref65}Rabbit centrin2 N-17-RSanta Cruz\#sc-27793-R; RRID: [AB_2082359](nif-antibody:AB_2082359){#interref70}Mouse γ-H2AX S139Merck Millipore\#05-636; RRID: [AB_309864](nif-antibody:AB_309864){#interref75}Mouse α-smooth actinSigma-Aldrich\#A2547; RRID: [AB_476701](nif-antibody:AB_476701){#interref80}Mouse p53Santa Cruz\#sc-126; RRID: [AB_628082](nif-antibody:AB_628082){#interref85}Rabbit p21Cell Signaling\#2947-S; RRID: [AB_823586](nif-antibody:AB_823586){#interref90}Rabbit β-actinCell Signaling\#4970; RRID: [AB_2223172](nif-antibody:AB_2223172){#interref95}Rabbit Histone H3Cell Signaling\#9715S; RRID: [AB_331563](nif-antibody:AB_331563){#interref100}Rabbit IL-8Abcam\#ab106350; RRID: [AB_10890102](nif-antibody:AB_10890102){#interref105}Rabbit NRF2Abcam\#ab62352; RRID: [AB_944418](nif-antibody:AB_944418){#interref110}Rabbit ERK1/2Cell Signaling\#4696; RRID: [AB_390780](nif-antibody:AB_390780){#interref115}Rabbit p-ERK1/2 Thr202/Tyr204Cell Signaling\#9101S; RRID: [AB_331646](nif-antibody:AB_331646){#interref120}Rabbit MCAKBethyl Lab\#A300-807A-M; RRID: [AB_577221](nif-antibody:AB_577221){#interref125}Mouse N-cadherinBD Bioscience\#610920; RRID: [AB_2077527](nif-antibody:AB_2077527){#interref130}Mouse E-cadherinBD Bioscience\#610181; RRID: [AB_397580](nif-antibody:AB_397580){#interref135}Mouse VimentinBD Bioscience\#550513; RRID: [AB_393716](nif-antibody:AB_393716){#interref140}Rabbit p-EGFR Tyr1068Cell Signaling\#3777S; RRID: [AB_2096270](nif-antibody:AB_2096270){#interref145}Rabbit p-HER2 Tyr1221/1222Cell Signaling\#2243S; RRID: [AB_490899](nif-antibody:AB_490899){#interref150}Rabbit p-c-Met Tyr1234/1235Cell Signaling\#3077S; RRID: [AB_2143884](nif-antibody:AB_2143884){#interref155}**Chemicals, Peptides, and Recombinant Proteins**Doxycycline hyclateSigma-Aldrich\#D9891RO-3306Sigma-Aldrich\#SML0569TrastuzumabGenentechN/AErlotinibSanta Cruz\#sc-202154PHA-66752Sigma-Aldrich\#PZ0147NSC23766Millipore\#553502ReparixinCayman Chemical\#21492SCH563705MedChem Express\#HY-10011PD98058Sigma-Aldrich\#P215PP2Sigma-Aldrich\#P0042H2O2Sigma-Aldrich\#H1009N-acetyl cysteineSigma-Aldrich\#A9165MitotempoSigma-Aldrich\#SML0737Nutlin-3Sigma-Aldrich\#N6287DoxorubicinSigma-Aldrich\#D1515ApocyninSanta Cruz\#sc-203321Antimycin-AAbcam\#ab141904DMEM/F12Sigma-Aldrich\#D8437DMEMThermo Fisher Scientific\#41966-029RPMIThermo Fisher Scientific\#21875-034EGFSigma-Aldrich\#E4127InsulinInvitrogen\#12585-014HydrocortisoneSigma-Aldrich\#H4001Cholera toxinSigma-Aldrich\#C8052Penicillin/StreptomycinThermo Fisher Scientific\#15140-122Horse serumSigma-Aldrich\#H1138FBS\#10500-064Tet-free FBSHyclone\#SH30070.03TBlasticidinGeneron\#2805-10Geneticin (G418)Thermo Fisher Scientific\#10131027PolybreneSigma-Aldrich\#H9268Immobilized trypsin, TPCK treated agarose resinThermo Fisher Scientific\#20230CellTracker Green CMFDAThermo Fisher Scientific\#C2925CellTracker CM-Dil Dye RedThermo Fisher Scientific\#C7001TricaineSigma-Aldrich\#E10521Formaldehyde 16%Thermo Fisher Scientific\#28908FormalinSigma-Aldrich\#HT5012Phalloidin Alexa A568Molecular Probes\#12380Hoechst 33342Molecular Probes\#H3570MitosoxMolecular Probes\#M36008ProLong anti-fade mounting mediumMolecular Probes\#P36934BSASigma-Aldrich\#A9647Lipofectamine 2000Invitrogen\#11668027Lipofectamine RNAi MaxInvitrogen\#13778075Power SYBR Green PCR Master MixApplied Biosystems\#4367659RIPA BufferThermo Scientific\#89901Complete Mini Protease Inhibitor CocktailRoche\#11836153001Phosphatase inhibitor CocktailCell Signaling\#5870Bradford Protein AssayBio-Rad\#5000006Insulin-Transferrin-Selenium-Ethanolamine (ITS)Thermo Fisher Scientific\#51500-056Liberase Research GradeSigma-Aldrich5401020001Human IL-8R&D\#208-IL-010Human C-terminal ANGPTL4R&D\#4487-AN-050Human GDF-15Invitrogen\#EHGDF-15Human FGFSigma-Aldrich\#F0291**Critical Commercial Assays**ELISA GDF-15 kitThermo Fisher Scientific\#EHGDF15ELISA IL-8 kitAbcam\#ab46032ELISA PAI kitAbcam\#ab108891ELISA Mesothelin kitR&D\#DMSLN0ELISA Angiopoietin-like 4 kitThermo Fisher Scientific\#EHANGPTL4ELISA HMGB1 kitIBL\#ST51011RNAeasy kitQiagen\#74104High-capacity RNA-to-cDNA kitThermo Fisher Scientific\#4387406Power SYBR GreenThermo Fisher Scientific\#4367659Pierce LDH Cytotoxicity Assay kitThermo Fisher Scientific\#88953Senescent cells histochemical staining kitSigma-Aldrich\#CS0030-1KTCellular Reactive Oxygen Species detection kitAbcam\#Ab113851GSH/GSSH-Glo assayPromega\#V6611BCA Protein assayThermo Fisher Scientific\#23225Human phosphor-receptor tyrosine kinase array kitR&D\#ARY001BProteome Profiler Human XL Oncology array kitR&D\#ARY026Custom Human antibody array kitRayBiotech\#AAH-CUST-M**Deposited Data**Microarray DataArrayExpress[E-MTAB-6415](array-express:E-MTAB-6415){#intref0010}**Experimental Models: Cell Lines**MCF10AATCC\#CRL-10317MCF10A.PLK4[@bib31]N/AHaCaT.PLK4[@bib31]N/ABF.PLK4This workN/ARPE1.PLK4[@bib60]N/AMCF-7.PLK4This workN/AHCC1954.PLK4This workN/ABT-549Prof. Peter Schmid (QMUL)N/AMDA-MB-231Prof. Peter Schmid (QMUL)N/AMDA-MB-468Prof. Peter Schmid (QMUL)N/AHEK293MProf. David Pellman (DFCI)N/A**Experimental Models: Organisms/Strains**Mouse: *Mus musculus* C57BL/57 strainCharles RiverJAX C57BL/6JMouse: *Mus musculus* B6.129S2(C) -- *Cxcr2*^*tm1Mwm*^/JJackson Laboratory\#006848Zebrafish: *Danio rerio mitfa*^*w2/w2*^*; mpv17*^*a9/a9*^ (Casper)N/AN/A**Oligonucleotides**siRNAs -- See [Table S6](#mmc1){ref-type="supplementary-material"}N/AqRT-PCR primers -- See [Table S7](#mmc1){ref-type="supplementary-material"}N/A**Recombinant DNA**pLenti-CMV-TetR-BlastAddgene\#17492pLenti-CMV/TO-Neo-DEST.PLK4[@bib31]N/ApInducer.PLK4[@bib60]N/ApMD2.G VSV-GAddgene\#12259psPAX2 Gag-PolAddgene\#12260**Other**Vivaspin columns MWCO 5000 DaGE Healthcare\#28-9323-598-well chamber slidesCorning\#3541088-well chamber slides with glass bottomibidi\#80827

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Susana A. Godinho (<s.godinho@qmul.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cell Culture {#sec4.3.1}

Cell lines were maintained at 37°C with 5% CO~2~ atmosphere. Human mammary epithelial MCF10A cells were grown in DMEM/F12 supplemented with 5% donor horse serum, 20 ng/ml epidermal growth factor (EGF), 10 mg/ml insulin, 100 mg/ml hydrocortisone, 1 ng/ml cholera toxin, 100 U/ml penicillin and streptomycin. HaCat (human keratinocytes; gift from J. Marshall-QMUL), BF (primary human fibroblasts; gift from A. O'Loghlen-QMUL), MDA-468 and MDA-231 (breast cancer; gift from P. Schmid-QMUL) were grown in DMEM supplemented with 10% FBS and 100 U/ml penicillin and streptomycin. RPE-1 (human retinal epithelial) were grown in DMEM/F12 supplemented with 10% FBS and 100 U/ml penicillin and streptomycin. MCF-7, HCC1954 and BT-549 (breast cancer; gift from P. Schmid-QMUL) were grown in RPMI supplemented with 10% FBS and 100 U/ml penicillin and streptomycin. Tetracycline-free FBS was used to grow cells expressing the *PLK4* Tet-inducible construct, with the exception of MCF10A cells where horse serum was always used.

For 3D cultures, MCF10A cells were grown in the same medium with reduced horse serum (2%). To assay invasion in 3D cultures, cells were grown in a mix of matrigel: collagen-I, as previously described ([@bib2]). Growth factor-reduced matrigel with specific protein concentrations between 9 and 11 mg/ml was used. Note that due to the variability in the composition of the matrigel lots, we always tested the ability of cells with extra centrosomes to induce the formation of invasive protrusions (∼20%) before we use it for our experiments.

Collagen-I was used at 1.6 mg/ml. Cells were grown for 4 days in 3D cultures before quantifying invasion. 150--200 acini were scored per condition for each experiment.

### Mouse Mammary Organoids {#sec4.3.2}

Mammary gland organoids were prepared according to previously described methods ([@bib53]). Briefly, mammary glands from C57BL/6J female mice between 8 and 12 weeks of age were isolated. In the sterile hood, mammary glands were minced with a scalpel, and the small pieces were transfer to a collagenase solution in DMEM/F12 (2 mg/mL collagenase, 2 mg/mL trypsin, 5 % v/v fetal bovine serum (FBS), 5 μg/mL insulin and 50 μg/mL gentamicin) on a shaker (150 rpm) for 35 min at 37°C. Tubes were spun in a centrifuge at 1500 rpm for 10 min at room temperature and the pellet was kept as the epithelial fraction containing the organoids. After further digestion of the pellet with DNase (2 U/μL), three more short-pulse washes at 1500 rpm were done, and organoid density was calculated by manual counting on the microscope. The structures were seeded at a 2 organoids/μl density and embedded in a mixture of Matrigel: Collagen (3:7) on eight well chambers. Organoid medium (DMEM/F12 with 1% penicillin/streptomycin, 1% ITS and 2.5 nM FGF2) was added on top and invasive organoids were quantified after 4 days. Mammary organoids were fixed with formaldehyde 4% and stained with α-SMA, Phalloidin and Hoechst 33342. Images were taken with a 710 Zeiss laser scanning confocal microscope. We quantified 100 organoids per conditions for each experiment.

C57BL/6J WT animals were obtained from Charles River: <https://www.criver.com/products-services/find-model/jax-c57bl6j-mice?region=3616>. CXCR2-/- BALB/c mice (*Cxcr2*^*tm1Mwm*^ knock-out) were obtained from Jackson Laboratories ([@bib10]). WT littermates were used as controls. All animal experiments followed Home Office Guidelines determined by the Animals (Scientific Procedures) Act 1986.

### Zebrafish Embryo Xenograft Model {#sec4.3.3}

Zebrafish (*Danio rerio*) were handled in compliance with local animal care regulations (Queen Mary University of London) under the Animals (Scientific Procedures) Act 1986 and standard protocols. Fish were kept at 28°C in aquaria with day/night light cycles (10 hr dark/14 hr light periods). The developing embryos were kept in an incubator at constant temperature.

MCF10A cells (1x10^6^ cells) with normal or extra centrosomes (+DOX, 48 hrs) were stained in suspension with 10 mmol/L CellTracker Green CMFDA (Green) or 2.5 μg/ml CellTracker™ CM-DiI Dye (Red) during 30 min at 37°C. To remove unincorporated dye, cells were rinsed twice with PBS, and one third of the cells of each condition was mixed 1:1 for the co-injection experiments (∼300-400 cells per embryo). 48 hr old zebrafish embryos were dechorionated and anesthetized with tricaine (Sigma-Aldrich) prior to implantation of the labelled cells in the perivitelline cavity with a manual injector (Picospritzer III, Parker Hannifin Instruments). After injections, embryos were incubated at 34°C. Three separate experiments were carried out per condition. Counting of disseminated cells was done 24 hrs after injections under high magnification using a Zeiss Axioplan epifluorescence microscope.

### Mouse Tumor Organoids {#sec4.3.4}

MMTV-PyMT cell isolation and growth has been previously described ([@bib55]). Briefly, MMTV-PyMT tumors were isolated, mechanically minced and chemically digested using Liberase and DNase I in HBSS and passed through a 100 μm cell strainer. A single cell suspension of this PyMT primary tumor cells were seeded on a glass-bottom 8-well chamber at 2.5 x 10^3^ cells/chamber in a 2:1 mixture of Collagen-I (Corning) and Matrigel (Corning) yielding a final collagen concentration of 4 mg/ml and a final Matrigel concentration of 2 mg/ml. Tumor organoids were grown in conditioned media supplemented with 10X concentrated MEM media (DMEM/F12 supplemented with 2% FCS, 10 μg/ml Insulin, 20 ng/ml EGF and 1:50 L-Glutamax at 37°C and 5% CO2 during 7 days. Tumor organoids were fixed with formaldehyde 4% and stained with Phalloidin and Hoechst 33342. Images were taken with a 710 Zeiss laser scanning confocal microscope. The degree of branching and percentage of tubular and rounded structures was manually quantified. Organoid growth and tubular expansion was obtained as the total Phalloidin area/structure using Image J Software. We quantified 100 organoids per condition for each experiment.

Method Details {#sec4.4}
--------------

### Lentiviral Production and Infection {#sec4.4.1}

Cells expressing the inducible PLK4 construct were previously described ([@bib31]). Briefly, the lentiviral vectors pLenti-CMV-TetR-Blast and p-Lenti-CMV/TO-Neo-Dest expressing the PLK4 cDNA were used consecutively. Cell lines were initially infected with a lentivirus containing the TetR and selected using Blasticidin (5-10 μg/ml). After selection cells were secondarily infected with the PLK4 containing lentivirus and selected with Geneticin (100-200 μg/ml). The selected cells were maintained as a pool to make a cell population. To generate the HCC1954.PLK4 and BF.PLK4 cell lines we used the pInducer21 lentiviral vector in which the PLK4 cDNA was inserted using the Gateway system. In this case, positive cells were sorted according to GFP signal.

To generate lentivirus, HEK-293M cells were grown in antibiotic free medium and co-transfected with the lentiviral plasmid, VSV-G (pMD2.G) and Gag-Pol (psPAX2) using Lipofectamine 2000, according to the manufacturer's protocol. Lentivirus were harvested 24 and 48 hrs post infection and passed through a 0.45 μM syringe filter unit and stored at -80°C. To infect cells, 8 μg/ml polybrene was included to 1.5 ml of lentivirus and added on top of cells for 6 hrs. This process was repeated the following day and 48 hrs post initial infection. As specified above cells were treated with appropriate antibiotic for selection or amplified for cell sorting.

### Conditioned Media {#sec4.4.2}

Cells were seeded in a 6 well plate (-DOX: 0.7x10^5^ cells/well; +DOX: 0.9x10^5^ cells/well) and incubated for 2 days in the presence or absence of DOX (2 μg/ml) until they reached 80%-85% confluency. After incubation, cells were washed three times with PBS to remove DOX and 900 μl phenol-free DMEM/F12 medium without serum was added on top of the cells during 16 hrs. After that, the conditioned medium (CM) was collected, centrifuged at 2,000g for 10 min and filtered through a 0.2 μm pore filter. CM was mixed with 10X concentrated 3D media (final concentration 1x) before being added on top of the 3D cultures. Cells were always counted to discard effects due to differences on cell number. If a particular treatment decreased the final cell number, cell seeding was adjusted so that the same cell numbers were obtained at the time of CM collection.

Trypsin treatment of the CM was done by adding 50 μl of beads with immobilized trypsin (TPCK Treated Agarose Resin) to 1 ml of conditioned media and incubated overnight with rotation at 37°C. The following day beads were removed by centrifugation and the CM was added on top of 3D cultures.

Vivaspin columns with a 5kDa cut-off membrane were used to separate larger fractions (\>5kDa: proteins) from smaller fractions (\<5kDA: metabolites, small molecules). 2 ml of conditioned media were added to the columns and centrifuged at 5000g for 30 min. When drugs were present in the CM, Vivaspin columns were washed away with phenol-free DMEM/F12 medium using 2 successive centrifugations before resuspending the remainder CM with DMEM/F12.

### Chemicals {#sec4.4.3}

Doxycycline (DOX) was used at 2 mg/ml. The following doses of inhibitors were used: 5 μM R0-3306 (CDK1i), 40 μg/ml Trastuzumab (Herceptin, HER2 inhibitor), 0.5-4 μM Erlotinib (EGFR inhibitor), 1 μM PHA-66752 (c-met inhibitor), 25 μM NSC23766 (RAC1 inhibitor), 100 nM Reparixin (CXCR1/2 inhibitor), 100 nM SCH563705 (CXCR1/2 inhibitor), 20 μM PD98059 (ERK inhibitor), 5 μM PP2 (Src inhibitor), 100 μM H2O2 (Sigma), 5 mM NAC (Sigma), 0.5 mM Apocynin, 35 μM Antimycin-A, 10 μM Mitotempo, 5 μM Nutlin-3 and 100 ng/ml Doxorubicin (DoxoR).

### Recombinant Proteins {#sec4.4.4}

Recombinant proteins were used at the following concentrations: IL-8 (0.5 μg/ml, 208-IL-010), c-terminal fragment of Angiopoietin- like 4 (4 μg/ml) and GDF-15 (0.01 μg/ml).

### Indirect Immunofluorescence 2D {#sec4.4.5}

Cells plated in glass coverslips (2D) were washed in PBS and fixed with ice-cold methanol at -20⁰C for 10 min for centrin2 staining. Following fixation cells were permeabilized in 0.2% Triton X-100 in PBS for 5 min and blocked in blocking buffer (PBS, 5% BSA, 0.1% Triton X-100) during 30 min. Cells were then stained in primary antibodies diluted in blocking buffer for 60 min. Cells were washed with PBS and incubated 60 min with species-specific fluorescent secondary antibodies (Alexa-conjugated). DNA was stained with Hoechst 33342 (1:5000) for 5 min in PBS. Antibodies used included: anti-α-tubulin DM1α (1:1000), anti-centrin-2 N-17-R (1:100). For all conditions used in this work, centrosome amplification was determined as the percentage of mitotic cells containing extra centrosomes ([Table S1](#mmc1){ref-type="supplementary-material"}). For Ki67 staining (assess cell viability) or γH2AX (assess dsDNA breaks), cells were fixed with 4% of formaldehyde 15 min at room temperature and stained using anti-Ki 67 antibody (1:500) and anti-γH2AX (1:200) diluted in 0.25% BSA. Images were acquired using an inverted Nikon microscope coupled with a spinning disk confocal head (Andor) and analyzed with ImageJ (National Institute of Health, Bethesda, MD, USA). Proliferating cells were quantified as the percentage of Ki67 positive nuclei and dsDNA breaks were quantified as the number of γH2AX-positive foci per nucleus using the NIS-Elements software (Nikon).

To assess mitochondrial ROS, live cells were incubated with 5 μM Mitosox for 10 min at 37⁰C. Images were acquired using an inverted Nikon microscope coupled with a spinning disk confocal head (Andor). Images were analyzed with NIS-Elements software (Nikon). 100 cells in mitosis were used to quantify centrosome amplification per condition for each experiment.

### Indirect Immunofluorescence 3D {#sec4.4.6}

Immunostainings of 3D cultures were performed on partially embedded 3D acini and breast and tumor organoids, both plated on eight-well chambers, according to previous protocols ([@bib31], [@bib55]). Briefly, the media was removed and the structures were washed with PBS and fixed in 5% of formalin in PBS for 20 min at 37°C. After fixation cells were washed 3 times, 10 min each, with PBS: 100 mM glycine and permeabilized with 0.5% Triton X-100 in PBS for 10 min. Cells were blocked with 10% goat serum in IF buffer (130mM NaCl, 7 mM Na2HPO4, 3.5 mM NaH2PO4, 7.7 mM NaN3, 0.1% BSA, 0.2% Triton X-100, 0.05% Tween-20) for 1 hr at room temperature, and primary antibodies were incubated in this solution over night at 4°C. Cells were rinsed 3 times, 20 min each, with IF buffer. When required, cells were incubated with secondary antibodies for 1 hr at room temperature (Alexa-conjugated). Cells were washed twice with IF buffer and once with PBS followed by 10 min incubation with Hoechst 33342 (1:2500). 3D cultures were mounted in ProLong Antifade mounting medium. Antibodies used include anti Laminin-V AlexaFluor 488 conjugated (1:100) and α-smooth muscle actin (1:150). For f-actin staining 3D cultures were incubated with Phalloidin (1:100; AlexaFluor 568) for 60 min. Images were taken with a 710 Zeiss laser scanning confocal microscope.

### Long-Term Live-Cell Imaging {#sec4.4.7}

MCF10A cells plated in ibidi chambered slides were used for 3-D imaging. Cells were imaged on a Nikon Eclipse Ti-E inverted microscope equipped with a ORCA-Flash 4.0 camera, a precision motorized stage, and Nikon Perfect Focus, all controlled by NIS-Elements Software (Nikon). Microscope was enclosed within temperature and CO2-controlled environments that maintained an atmosphere of 37° C and 3%-5% humidified CO2. Phase contrast images were captured at every 10 minutes for 20 hrs with either Plan Fluor 10X (0.3 NA) or Plan Apo VC 20X (0.75 NA) objectives. Captured images from each experiment were analyzed using NIS-Elements software. Videos were played at 50 ms per frame.

### ELISAS {#sec4.4.8}

Levels of secreted proteins were assessed in the CM collected from cells with normal or extra centrosome numbers (+DOX) using commercially available ELISA kits, following manufacturer's instructions: GDF-15, IL-8, PAI, Mesothelin, Angiopoietin-like 4 and HMGB1. Briefly, CM, collected as described above (see CM section), and specific protein standards were loaded on the specific-antibody coated wells of the supplied microplate, which bind to the immobilized (capture) antibody. A sandwich is formed by the addition of the biotinylated antibody, binding to the chemokine on a different epitope from the capture antibody. A conjugated enzyme (Streptavidin-Peroxidase) was added into the assay. After incubation periods and wash steps specified by every supplier to remove unbound antibody from the plate, a substrate solution was added in order to obtain a measurable signal. The intensity of this signal was proportional to the concentration of the protein present in the CM. Assays were performed in triplicate, and absorbance at 450 nm was read on a plate reader.

### Nuclear Fraction Isolation {#sec4.4.9}

70% confluent cells on a 6-well plate were washed twice and scraped with PBS. This fraction was centrifuged at 850 g for 10 min to collect the cells. Cells were then lysed by 15 min incubation in hypotonic buffer (20 mM HEPES \[pH 7.6\], 20% glycerol, 10 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.1% Triton X-100, 25 mM NaF, 25 mM β-glycerophosphate, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 1 mM dithiothreitol, and protease inhibitors) supplemented with detergents (NP-40, 10%). After this incubation, nuclei were collected by centrifugation (14000 g for 1 min at 4◦C) and supernatant recovered as cytosolic fraction. This pellet, including mainly intact nuclei, was lysed in a rocking platform for 30 min with gentle agitation and nuclear soluble fractions were collected after centrifugation (14000 g for 10 min at 4◦C).

### Western Blotting {#sec4.4.10}

Cells were collected and resuspended in RIPA buffer supplemented with protease and phosphatase inhibitors. Protein concentration was quantified using the Bradford Protein Assay (20 μg was loaded per well). Protein samples were then resuspended in Laemmli buffer and separated on sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto PVDF membranes. Antibodies used included anti-p53 (1:1000), anti-p21 (1:1000), anti-β-actin (1:5000), anti-α-tubulin (1:2000), anti-Histone H3 (1:10000), anti-Interleukin-8 (1:1000), anti-NRF2 (1:1000), anti-ERK (1:1000), anti-pERK Thr202/Tyr204 (1:1000), pEGFR Tyr1068 (1:1000) anti-MCAK (1:1000), anti-N-cadherin (1:500), anti-E-Cadherin (1:500), anti-Vimentin RV202 (1:500), anti-pHER2 Tyr1221/1222 (1:1000) and anti-p-c-Met Tyr1234/1235 (1:1000). Western blots were developed using SRX-101A Konica Minolta and scanned. The intensity of the bands was measured by densitometry using ImageJ (National Institute of Health, Bethesda, MD, USA).

To assess the levels of p-Erk1/2, cells pre-treated with HER2 (Trastuzumab, 40 μg/ml, 1 hr) and CXCR1/2 (SCH563705, 100 nM, 1 hr) inhibitors and incubated with CM for 10 min.

### siRNA {#sec4.4.11}

siRNA was performed using Lipofectamine RNAiMax. 50 nM of siRNA was used per well in a 6-well plate. Cells were incubated with the transfection mix for 6 hrs, washed and normal growth medium was added. Cells were analyzed 48 hrs post transfection. siRNAs used are described in [Table S5](#mmc5){ref-type="supplementary-material"}. To assess invasion in the siRNA mini screen, 150-200 acini were quantified per conditions in each experiment.

### qRT-PCR {#sec4.4.12}

RNA was prepared using the Qiagen RNAeasy kit according to the manufacturer's instructions. 200 ng of RNA was used to produce cDNA using the High-Capacity RNA-to-cDNA kit according to the manufacturer's instructions. For qRT-PCR we used Power SYBR Green followed by analysis with 7500 Real Time PCR system (Applied Biosystems). All primers used for qRT-PCR are described in [Table S6](#mmc1){ref-type="supplementary-material"}.

### Secretomics Optimization {#sec4.4.13}

Secretome analysis was done in the CM collected from cells with normal or extra centrosomes (+DOX, 48 hrs). Since secreted proteins are often masked by high amounts of protein supplements in the culture medium, we used a modified serum-deprived method previously described ([@bib1]). After three washes with PBS, DMEM/F12phenol-free medium without serum was added on top of the cells during 16 hrs. After this incubation, CM was collected and cells were counted. The collected CM was assessed for protein concentration, measured using Bradford Protein Assay. Lactate dehydrogenase (LDH) detection was also assessed using a the LDH Cytotoxicity Assay Kit, as a measure of cell death. Samples were concentrated using Vivaspin Columns (Vivaspin MWCO 5000 Da) before proceeding to the protein analysis by mass spectrometry.

### Mass Spectrometry {#sec4.4.14}

Proteomics experiments were performed using mass spectrometry as reported before ([@bib11], [@bib58]). Briefly, enriched CM proteins were digested with trypsin and resultant peptides were desalted using C18 plus carbon top tips (Glygen corparation, TT2MC18.96) and eluted with 70% acetonitrile (ACN) with 0.1% formic acid. Dried peptides were dissolved in 0.1% TFA and analyzed by nanoflow LC-MS/MS in an ultimate 3000 RSL nano instrument coupled on-line to a Q Exactive plus mass spectrometer (Thermo Fisher Scientific). A PepMap RP 75 μm ID x 150 mm column was used for peptide separation. Gradient elution was from 3% to 35% buffer B in 120 min at a flow rate 250nL/min with buffer A being used to balance the mobile phase (buffer A was 0.1% formic acid in water and B was 0.1% formic acid in ACN). The mass spectrometer was controlled by Xcalibur software (version 4.0) and operated in the positive ion mode. The spray voltage was 1.95 kV and the capillary temperature was set to 255°C. The Q-Exactive plus was operated in data dependent mode with one survey MS scan followed by 15 MS/MS scans. The full scans were acquired in the mass analyzer at 375- 1500m/z with the resolution of 70 000, and the MS/MS scans were obtained with a resolution of 17 500. MS raw files were converted into Mascot Generic Format using Mascot Distiller (version 2.5.1) and searched against the SwissProt database (release December 2015) restricted to human entries using the Mascot search daemon (version 2.5.0) ([@bib56]). Allowed mass windows were 10 ppm and 25 mmu for parent and fragment mass to charge values, respectively. Variable modifications included in searches were oxidation of methionine and pyro-glu (N-term). Label-free quantification was performed by calculating the peak areas of extracted ion chromatograms (XICs) for the respective peptide ion. Mass and time windows were 7ppm and 1.5 minutes respectively. Pescal was used to automate the generation of XICs as described ([@bib80]). To reliably differentiate the extracellular components from intracellular contaminants, a filtering step was applied using different Databases: Gene ontology, Secreted Protein Database and Signal Peptide Database. From the Secreted Protein Database ranks 0 to 2 were considered as belonging to the extracellular compartment.

### Analyses of the Extracellular Protein Compartment {#sec4.4.15}

To define the proteins from the mass spectrometry data that belonged to the extracellular compartment we used several databases, including Gene ontology, Secreted Protein Database and Signal Peptide Database. Secreted protein Database (SPD) consists of a core dataset and a reference dataset ([@bib16]). The core dataset contains 18 152 secreted proteins retrieved from Swiss-Prot/TrEMBL, Ensembl, RefSeq and CBI-Gene. We used a combined automatic and manual processing to collect as much secreted proteins as possible. The dataset Rank0 from Swiss-Prot includes some partial sequences without the N- or C-termini. Given that most of the signal peptides are located at the N-terminal of proteins, we eliminated the entries without N-terminal methionine (Met, M) in CBI-Gene, Ensembl, Swiss-Prot/TrEMBL and RefSeq in our prediction results. Proteins in the datasets of Rank1, 2, 3 all have N-terminal Met. For our analyses we selected proteins that ranked 0-2 as belonging to the extracellular compartment since proteins in rank 3 have lower probability of belonging to the extracellular compartment ([@bib16]).

### β-Galactosidase Staining {#sec4.4.16}

Positive senescent cells were scored using a commercial available kit (Senescence Cells Histochemical Staining Kit). Briefly, cells in 6-well plates were washed, fixed and stained overnight with a staining mixture at 37°C without CO~2~. Under these conditions, β-galactosidase activity is easily detectable in senescent cells, but undetectable in quiescent, immortal, or tumor cells. Percentage of positive cells was counted manually with a microscope. We quantified 1500-2000 cells per conditions for each experiment. For the H2O2 treatments, cells were incubated only 48 hrs with H2O2 after which cells were washed and left from the appropriate time (6-10 days) before assessing senescence. As control positive, cells were treated with 100 ng/ml DoxoR for the entire duration of the experiment.

### Measure of ROS Production {#sec4.4.17}

ROS was measured using DCFDA (Cellular Reactive Oxygen Species Detection Assay Kit), a cell permeable fluorogenic dye that measures hydroxyl, peroxyl and other reactive oxygen species (ROS) activity within the cell. Briefly, cells were plated after 48 hrs of DOX treatment at a low confluency overnight (20x10^4^ cells/ well) in 96 well transparent bottom black-plate. The following day, the media was removed and 20 μM of DCFDA was added to the corresponding wells and incubated for 30 min at 37°C. The dye was washed away before reading. Positive controls were treated with 25 μM DoxoR for 3 hrs. The signal was detected by fluorescence spectroscopy with maximum excitation and emission spectra of 495 nm and 529 nm respectively.

ROS production was also assessed through the detection of oxidized proteins. Here we measure the total amount of oxidized (GSSG) and reduced (GSH) glutathione using bioluminescent signals, according to manufacturer's instructions (GSH/GSSG-Glo™ Assay). Briefly, cells were plated at a low confluency overnight (12x10^4^ cells/ well) in 96 well transparent bottom white-plate. The following day, the media was removed and reduced glutathione lysis reagent or oxidized glutathione lysis reagent were added to the corresponding wells and shake for 5 min at RT. Luciferin generation and detection reagent were added subsequently for 30 and 15 min, respectively. The bioluminescent signal was read per well using a plate reader luminometer. Final ratios were normalized to protein concentration, which was determined per well using BCA Protein Assay Kit. NAC (5 mM) and Apocynin (0.5 mM) were added at time of centrosome amplification induction (48 hrs) and DoxoR treatment was performed for 3 hrs (25 μM).

### Human Phospho-Receptor Tyrosine Kinase Array {#sec4.4.18}

RTK activation was assessed using an antibody-based array (Human Phospho-Receptor Tyrosine Kinase Array Kit) following manufacturer's instructions. Briefly, cells were treated for 48hrs with CM collected from control cells and cells with extra centrosomes (+DOX, 48hrs) and supplemented with completed medium. After incubation, cells were lysed using a lysis buffer provided by the kit and protein concentration was determined using Bradford (Bio-Rad). 300 μg of protein cell lysates were added on top of the membranes and incubated overnight at 2-8°C on a rocking platform. Thereafter, a pan anti-phosphotyrosine antibody was added to detect the activated RTKs. After several washes of the membranes, phosphorylated RTKs were spotted using a Chemi Reagent Mix and developed in an autoradiography film cassette. Following quantification of scanned images using ImageJ software (National Institute of Health, Bethesda, MD, USA) by densitometry, the relative activation of specific phosphorylated RTKs between normal and cells with extra centrosomes was plotted.

### Human XL Oncology Array Kit {#sec4.4.19}

We screened protein secretion using a membrane-based sandwich immunoassay (Proteome Profiler Human XL Oncology Array Kit), following manufacturer's protocol. Briefly, cell culture supernatants collected from normal or cells with extra centrosomes plated in 6-well plates were diluted and incubated overnight with the membrane arrays. These membranes contain a set of capture antibodies, spotted in duplicate, that bind to specific target proteins. The membranes were then washed to remove unbound material and incubated with a cocktail of biotinylated detection antibodies. Streptavidin-HRP and chemiluminescent detection reagents were then applied, and the signal was captured using autoradiography films. The intensity of every spot was measured by densitometry using ImageJ (National Institute of Health, Bethesda, MD, USA) and the relative intensity versus control was calculated and depicted.

### Human SASP Array Kit {#sec4.4.20}

MCF10A.PLK4 and RPE-1.PLK4 cells were seeded in a 6 well plate \[MCF10A.PLK4: 0.7x10^5^ cells for -DOX; 0.9x10^5^ for +DOX and 2x10^5^ for DoxoR (100ng/mL) and RPE-1.PLK4: 0.5x10^5^ cells for -DOX; 0.75x10^5^ for +DOX and 1.1x10^5^ for DoxoR (100ng/mL)\] and incubated for 2 days in the presence or absence of DOX. For 48 hrs analyses, CM was collected as described above after DOX treatment. For 7 days analyses, cells were split at day 2 and day 4 and serum free medium was added at day 6 and collected at day 7. Senescence-Associated Secretory Phenotype (SASP) was screened using a membrane-based sandwich immunoassay (Custom C-series Human Antibody Array), following manufacturer's protocol. We defined a set of known SASP components, including: including IL-8, IL-6, uPar, MIP-3α, MCP-1, GRO -a, -b, -c and IL-1β, based on previous work ([@bib19]), that were spotted in duplicate on a membrane provided by RayBiotech. Cell culture supernatants collected from cells with normal or extra centrosomes and cells treated with DoxoR were diluted in serum-free media and blocking solution. Volume equivalent to 2.10^5^ cells/condition was incubated overnight with the membrane arrays. The membranes were then washed to remove unbound material and incubated with a cocktail of biotinylated detection antibodies. Streptavidin-HRP and chemiluminescent detection reagents were then applied, and the signal was captured using autoradiography films. The intensity of every spot was measured by densitometry using ImageJ (National Institute of Health, Bethesda, MD, USA) and the relative intensity versus control was calculated and depicted.

### Microarray Analysis and GSEA {#sec4.4.21}

Total RNA was extracted from MCF10A.PLK4 untreated (-DOX) or treated with DOX (+DOX) for 48 hrs using the RNeasy kit. RNA was hybridized against the Affymetrix HG-U133_Plus_2 microarrays according to manufacturer's instructions. Three biological replicates (3 -DOX and 3 +DOX) were analyzed with two technical replicates each. Genes differentially regulated between --DOX and +DOX groups were identified using limma with a false discovery rate (FDR) \<0.05. Gene set enrichment analysis (GSEA) ([@bib70]) was performed to investigate whether gene expression profiles of MCF10A cells with extra centrosomes (+DOX, 48 hrs) show bias towards specific signatures (<http://software.broadinstitute.org/gsea/msigdb>). In the GSEA, genes were ranked by Z score corresponding to false discovery rate (FDR) adjusted p values of the expression differences between normal cells and cells with extra centrosomes. 100,000 permutations were performed to assess the statistical significance of the enrichment score. The Gene Set for NRF2-regulated genes can be found here: <http://software.broadinstitute.org/gsea/msigdb/cards/NFE2L2.V2.html>.

### CCLE Expression Analysis {#sec4.4.22}

Raw mRNA abundance values for cell lines were obtained from the Cancer Cell Line Encyclopedia (CCLE) ([@bib3]). Expression values for a subset of 14 cell lines were quantile normalized using Robust Multi-array Average (RMA). Each cell line was assigned to a comparative group based on its centrosome amplification; high (BT-549, CAL-120, HCC-1937, Hs578T, MDA-231), intermediate (HCC-1954, HCC-38, BT-474, HCC-1143, SK-BR-3, JIMT-1), and low (BT-20, MDA-468, MCF-7) ([Figure 7](#fig7){ref-type="fig"}C). Boxplots of the mRNA abundance levels of cell lines appertaining to each group were generated for a group of pro-invasive factors.

### Exosomes and Microvesicle Isolation {#sec4.4.23}

Isolation of microvesicles and exosomes was done by differential ultracentrifugation as described previously ([@bib20]). Briefly, CM was collected as described above and cell debris was pelleted by centrifugation at 500*g* for 10 min. Microvesicles fraction was collected by centrifugation at 12,000*g* for 20 min. The supernatant was then centrifuge at 100,000*g* for 70 min in order to obtain the exosomes. The exosome pellet was washed in 20 ml of phosphate-buffered saline (PBS) and collected by ultracentrifugation at 100,000*g* for 70 min (Beckman Ti70). Both microvesicles and exosomes were resuspended in 3D media up to the initial volume in order to test their role in invasion.

Data and Software Availability {#sec4.5}
------------------------------

Microarray data of control MCF10A.PLK4 cells and MCF10A.PLK4 cells treated with DOX (48 hrs) to induce centrosome amplification is publicly available at ArrayExpress, accession number [E-MTAB-6415](array-express:E-MTAB-6415){#intref0035}.

Quantification and Statistical Analysis {#sec4.6}
---------------------------------------

### Statistics {#sec4.6.1}

Appropriate statistical tests were applied as per described in each legend using GraphPad Prism 5.0. Briefly, student's *t*-tests were used for comparisons between two groups. One-way ANOVA with Tukey post hoc test were used for comparison of three or more groups with one independent variable. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001, ^∗∗∗∗^*P* \< 0.0001, ns not significant.
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